Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | YAP1 | P46937 | 1/20 | 0.61 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.61 |
| ▸ | ME3 | Q16798 | 1/20 | 0.61 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.58 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7735744 | 0.85 | L3MBTL1 (0.49) | MAPTKMT2AYAP1TEAD4ME3 | |
| SCHEMBL29675219 | 0.82 | GAA (0.85) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL10055001 | 0.82 | GAA (0.85) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL501924 | 0.82 | GAA (0.85) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL16332685 | 0.82 | YAP1 (0.71) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL18966710 | 0.82 | YAP1 (0.67) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL13592382 | 0.82 | MAPT (0.68) | HPGDMAPTMEN1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL1804763 | 0.81 | GAA (0.82) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL17275229 | 0.79 | YAP1 (0.72) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL2184247 | 0.79 | HPGD (0.89) | HPGDMAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044021-B1 | PROCESS FOR PREPARING REMIFENTANIL, INTERMEDIATES THEREOF, USE OF SAID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION | KERN PHARMA S L (ES) | 2010-03-31 | — | — | EP | disclosed |
| US-20100016601-A1 | PROCESS FOR PREPARING REMIFENTANIL, INTERMEDIATES THEREOF, USE OF SAID INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF | KERN PHARMA, S.L. | 2010-01-21 | — | — | US | disclosed |
| EP-2044021-A1 | PROCESS FOR PREPARING REMIFENTANIL, INTERMEDIATES THEREOF, USE OF SAID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION | Kern Pharma, S.L. (ES) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007144391-A1 | PROCESS FOR PREPARING REMIFENTANIL, INTERMEDIATES THEREOF, USE OF SAID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION | KERN PHARMA, S.L. (ES) | 2007-12-21 | — | — | WO | disclosed |
| EP-1867635-A1 | Process for preparing remifentanil, intermediates thereof, use of said intermediates and processes for their preparation | KERN PHARMA, S.L. (ES) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016601-A1 | PROCESS FOR PREPARING REMIFENTANIL, INTERMEDIATES THEREOF, USE OF SAID INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF | OPRK1, CYP3A43, CYP3A4 | HPGD 115/4885MAPT 3123/4885MEN1 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.